Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sacroplasmic reticulum
Corresponding Author
Geir Olve Skeie MD
Department of Neurology, University of Bergen, Bergen, Norway
Department of Neurology, University of Bergen, Bergen, NorwaySearch for more papers by this authorPer Kristian Lunde PhD
Institute for Experimental Medical Research, University of Oslo, Oslo, Norway
Search for more papers by this authorOle M. Sejersted MD
Institute for Experimental Medical Research, University of Oslo, Oslo, Norway
Search for more papers by this authorÅse Mygland MD
Department of Neurology, Vest-Agder Central Hospital, Kristiansand, Norway
Search for more papers by this authorJohan A. Aarli MD
Department of Neurology, University of Bergen, Bergen, Norway
Search for more papers by this authorNils Erik Gilhus MD
Department of Neurology, University of Bergen, Bergen, Norway
Search for more papers by this authorCorresponding Author
Geir Olve Skeie MD
Department of Neurology, University of Bergen, Bergen, Norway
Department of Neurology, University of Bergen, Bergen, NorwaySearch for more papers by this authorPer Kristian Lunde PhD
Institute for Experimental Medical Research, University of Oslo, Oslo, Norway
Search for more papers by this authorOle M. Sejersted MD
Institute for Experimental Medical Research, University of Oslo, Oslo, Norway
Search for more papers by this authorÅse Mygland MD
Department of Neurology, Vest-Agder Central Hospital, Kristiansand, Norway
Search for more papers by this authorJohan A. Aarli MD
Department of Neurology, University of Bergen, Bergen, Norway
Search for more papers by this authorNils Erik Gilhus MD
Department of Neurology, University of Bergen, Bergen, Norway
Search for more papers by this authorAbstract
Myasthenia gravis (MG) patients with thymoma often have antibodies against the calcium-release channel of the sarcoplasmic reticulum (SR) in striated muscle, the ryanodine receptor (RyR). RyR function can be tested in vitro by measuring the degree of [3H]-ryanodine binding to SR. In this study, sera from 9 out of 14 MG patients containing RyR antibodies inhibited [3H]-ryanodine binding to SR membranes from rat skeletal muscle. The 9 patients with antibodies inhibiting ryanodine binding had more severe MG than those with noninhibiting antibodies (P = 0.006). Sera from MG patients with acetylcholine receptor and titin muscle antibodies but no antibodies against RyR and blood-donor sera did not have an inhibiting effect in the [3H]-ryanodine binding assay. The results show that RyR antibodies in MG patients have high affinity for the RyR, and that the binding of antibodies probably affects calcium release from SR by locking the RyR ion channel in a closed position. © 1998 John Wiley & Sons, Inc. Muscle Nerve 21:329–335.
References
- 1 Aarli JA, Stefansson K, Marton LSG, Wollmann RL: Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990; 82: 284–288.
- 2
Asaka T,
Ishiaka N,
Iwasa K,
Takamori M:
Striational autoantibodies in myasthenia gravis modulate calcium-induced calcium release from sarcoplasmatic reticulum [abstract].
J Neuroimmunol
1994;
54:
150.
10.1016/0165-5728(94)90250-X Google Scholar
- 3 Chen SRW, Zhang L, MacLennan DH: Antibodies as probes for Ca2+ activation sites in the Ca2+ release channel (ryanodine receptor) of rabbit skeletal muscle sarcoplasmic reticulum. J Biol Chem 1993; 268: 13414–13421.
- 4 Coronado R, Morrissette J, Sukhareva M, Vaugham DM: Structure and function of ryanodine receptors. Am J Physiol 1994; 266: c1485–c1504.
- 5 Emlen W, Holers VM, Arend WP, Kotzin B: Regulation of nuclear antigen expression on the cell surface of human monocytes. J Immunol 1992; 148: 3042–3048.
- 6 Favero TG, Zable AC, Bowman MB, Thompson A, Abramson JJ: Metabolic end products inhibit sarcoplasmic reticulum Ca2+ release and [3H]ryanodine binding. A Appl Physiol 1995; 78: 1665–1672.
- 7 Gautel M, Lakey A, Barlow PD, Holmes Z, Scales S, Leonard K, Labeit S, Myglandå, Gilhus NE, Aarli JA: Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993; 43: 1581–1585.
- 8 Gross WL, Schmitt WH, Csernok E: ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 1993; 91: 1–12.
- 9 Lefvert AK, BergstrøSm K, Matell G, Osterman PO, Pirskanen R: Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978; 41: 394–403.
- 10 Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD: Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic value. Neurology 1976; 26: 1054–1059.
- 11 Lindstrom J: Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome. Annu Rev Immunol 1985; 3: 109–131.
- 12 Lunde PK, Sejersted OM: [3H] Ryanodine binding to small samples of skeletal muscle. Scand J Clin Lab Invest (in press).
- 13 Ma J, King N, Chen SL, Penny R, Breit SN: Antibody penetration of viable human cells: II. Anti-RNP antibodies binding to RNP antigen expressed on cell surface, which may mediate the antibody internalisation. Clin Exp Immunol 1993; 93: 396–404.
- 14 Meissner G, El-Hashem A: Ryanodine as a functional probe of the skeletal muscle sarcoplasmic reticulum Ca2+ release channel. Mol Cell Biochem 1992; 114: 119–123.
- 15 Mohan S, Barohn RJ, Jackson CE, Krolick KA: Evaluation of myosin-reactive antibodies from a panel of myasthenia gravis patients. Clin Immunol Immunopathol 1994; 70: 266–273.
- 16 Morgan BP: Effects of the membrane attack complex of complement on nucleated cells, in CM Parker (ed): Current Topics in Microbiology and Immunology. Heidelberg, Springer-Verlag, 1992, vol 178, pp 115–140.
- 17 Mygland Å, Tysnes OB, Aarli JA, Flood PR, Gilhus NE: Myasthenia gravis patients with a thymoma have antibodies against a high molecular weight protein in sarcoplasmatic reticulum. J Neuroimmunol 1992; 37: 1–7.
- 18 Mygland Å, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE: Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992; 32: 589–591.
- 19 Mygland Å, Aarli JA, Matre R, Gilhus NE: Ryanodine receptor antibodies related to severity of thymoma-associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994; 57: 843–846.
- 20 Nielsen VK, Paulson OB, Rosenkvist J, Holsøe E, Lefvert AK: Rapid improvement of myasthenia gravis after plasma exchange. Ann Neurol 1982; 11: 160–169.
- 21 Ohta M, Ohta K, Itoh N, Kurobe M, Hayashi K, Nishitani H: Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: identification of anti-myosin, actomyosin, actin and α-actinin antibodies by a solid-phase radioimmunoassay and a Western blotting analysis. Clin Chim Acta 1990; 187: 255–264.
- 22 Oosterhuis HJGH, Limburg PC, Hummel-Tappel E: Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci 1983; 58: 371–385.
- 23 Pagala M, Nandakumar NV, Venkatachari SAT, Ravindran K, Namba T, Grob D: Responses of intercostal muscle biopsies from normal subjects and patients with myasthenia gravis. Muscle Nerve 1990; 13: 1012–1022.
- 24 Skeie GO, Mygland Å, Aarli JA, Gilhus NE: Tinin antibodies in patients with late-onset myasthenia gravis: clinical correlations. Autoimmunity 1995; 20: 99–104.
- 25 Skeie GO, Bartoccioni E, Evoli A, Aarli JA, Gilhus NE: Ryanodine receptor antibodies are associated with severe myasthenia gravis. Eur J Neurol 1996; 3: 136–140.
- 26 Takeshima H, Masamitsu I, Takekura H, Miyuki N, Kunu J, Minowa O, Takano H, Noda T: Excitation-contraction uncoupling in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature 1994; 369: 556–559.
- 27 Treves S, Chiozzi P, Zorzato F: Identification of the domain recognized by anti-(ryanodine receptor) antibodies which affect Ca2+ induced Ca2+ release. Biochem J 1993; 291: 757–763.
- 28 Williams CL, Lennon VA: Thymic B-lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, α-actinin or actin. J Exp Med 1986; 164: 1043–1059.
Citing Literature
